Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

In an interview with Targeted Oncology, Christopher Chambers, MD, discussed how primary care physicians are involved with the diagnosis of cancer and the challenges faced with early detection.

Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.